Respiratory Infections

FTD SARS-CoV-2 Assay

The FTD SARS-CoV-2 Assay is a real-time PCR test used to detect the new coronavirus SARS-CoV-2 causing COVID-19. The FTD SARS-CoV-2 Assay uses the same protocol, including PCR cycling profile, as other FTD respiratory assays.

Kit description:

• Single-well, dual target assay covering highly conserved regions within ORF1ab and N gene
• Validated specimen types include nasopharyngeal and oropharyngeal swabs
• Robust dual target design for high sensitivity and specificity

FTD SARS-CoV-2 Assay

Dual target design reduces inconclusive results and the need for repeat testing
• in silico analysis using more than 900 sequences shows 100% detection rate
• Uses the same setup protocol and thermal-cycling profile as other FTD assays

---

Assay | Target Region | Detection Channel |
--- | --- | --- |
SARS-CoV-2 | N | FAM |
| ORF1ab | FAM |
| IC | Cy5 |

1 FTD SARS-CoV-2 assay target regions

[siemens-healthineers.com/ftd-sars-cov-2-assay]
Fast Track Diagnostics SARS-CoV-2 Assay

Kit information:

<table>
<thead>
<tr>
<th>FTD SARS-CoV-2 Assay</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Product numbers</td>
<td>SMN 11416302</td>
</tr>
<tr>
<td>Kit size</td>
<td>96 tests/kit</td>
</tr>
<tr>
<td>Number of primer/probe mix</td>
<td>1 for detection of SARS-CoV-2 and Internal control</td>
</tr>
<tr>
<td>Kit components</td>
<td>Primer/probe mix</td>
</tr>
<tr>
<td></td>
<td>Enzyme and buffer</td>
</tr>
<tr>
<td></td>
<td>Internal control (Equine arteritis virus)</td>
</tr>
<tr>
<td></td>
<td>Positive and negative controls</td>
</tr>
<tr>
<td>Validated Extraction method</td>
<td>NucliSENS easyMAG (bioMerieux)</td>
</tr>
<tr>
<td>Validated Thermocycler</td>
<td>Applied Biosystems 7500 Real-Time PCR System (Thermo Fisher Scientific)</td>
</tr>
</tbody>
</table>

FTD SARS-CoV-2 Diagnostic Performance

- Positive Percent Agreement: 100% (91.8-100, 95% CI)
- Negative Percent Agreement: 100% (88.7-100, 95% CI)

Internal data on file.

FTD assays use the same setup protocol and thermal-cycling profile, enabling consolidation of respiratory testing into batch runs.

This is especially important during outbreaks, when testing for specific respiratory pathogens can be implemented without any disruption to other routine laboratory testing.

---

1CE-IVD labelled for diagnostic use in the EU. Pursuing WHO emergency use listing (EUL). This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21. U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

2CE-IVD labelled for diagnostic use in the EU. For research use only (RUO) in the U.S.

†FTD SARS-CoV-2 Instructions for Use.

All associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. All other trademarks and brands are the property of their respective owners.

Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.

Siemens Healthineers Headquarters
Siemens Healthcare GmbH
Henkestr. 127
91052 Erlangen, Germany
Phone: +49 9131 84-0
siemens-healthineers.com

Legal Manufacturer
Fast Track Diagnostics
Luxembourg S.à.r.l.
29, rue Henri Koch
4354 Esch-sur-Alzette
Luxembourg

for the Product
Fast Track Diagnostics Assays